The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...

Stem cell therapy is emerging as a potential treatment for different conditions in endocrinology, including diabetes and ...

The FDA has approved Merilog, the first-ever rapid-acting insulin biosimilar for diabetes treatment that helps manage blood ...

The global Insulin Delivery Devices Market was valued at USD 30.9 billion in 2022 and is expected to grow significantly, ...

These common breakfast foods can cause dangerous blood sugar spikes. Dietitians reveal what to avoid to help manage diabetes ...

Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...

The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for improving glycemic control ...

Mariposa California's original daily updated online newspaper is the premier site for news and information on Yosemite, ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced ...

DexCom , Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM) systems for diabetes management with a market capitalization of $34.8 billion, finds itself at a critical juncture as it ...

Peptide therapy enhances targeted medicine, utilizing specific peptides for effective treatment of cancer, metabolic disorders, and neurodegenerative diseases.

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.